This is a working overview of BPC-157, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
| Property | Value | Notes |
|---|---|---|
| Dry powder storage | -20 °C or below | Desiccated and protected from light |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw cycling |
| Reconstitution solvent | Water or buffered saline | Near-neutral pH is generally preferred |
| Identity confirmation | Mass spectrometry | Matches expected monoisotopic mass |
| Purity assessment | Reverse-phase HPLC | Reported as main-peak area percentage |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
There are many causes of acute liver failure aside from acetaminophen toxicity; these include viral hepatitis—including hepatitis A (rarely), hepatitis B, hepatitis C (rarely), hepatitis E (especially in pregnant women), Epstein–Barr virus, cytomegalovirus and varicella zoster virus -- Wilson's disease, the toxin of the death cap mushroom (Amanita phalloides), alcohol, autoimmune hepatitis, Budd–Chiari syndrome, other medications (including halothane, hormonal contraception, and isoniazid), recreational drugs (including ecstasy [1]) and, rarely, tumours infiltrating the liver. In patients with non-acetaminophen acute liver failure, the following criteria were identified as being associated with a poor prognosis:
==== Speech by Pedro Castillo ==== Against the backdrop of the ongoing political crisis, with parliamentary groups refusing to grant confidence to the government and even loyal ministers Roberto Sánchez and Hernando Cevallos expressing dissatisfaction, President Pedro Castillo gave a speech at 6:00 p.m. on 4 February 2022. In it, he announced a cabinet reshuffle and reorganization, without specifying whether he intends to replace the president of the council. At the time of the speech, a demonstration was taking place in front of the Government Palace demanding the resignation of Héctor Valer and against the appointment of the Minister of Women Katy Ugarte, who had spoken out against education in gender history and LGBT, in April 2021.
=== Maximum depositional age === Some of the most important information we can get from detrital zircon ages is the maximum depositional age of the referring sedimentary unit. The sedimentary unit cannot be older than the youngest age of the analyzed detrital zircons because the zircon should have existed before the rock formation. This provides useful age information to rock strata where fossils are unavailable, such as the terrestrial successions during Precambrian or pre-Devonian times. Practically, maximum depositional age is averaged from a cluster of youngest age data or the peak in age probability because the youngest U-Pb age within a sample is almost always younger with uncertainty.
Sources: en.wikipedia.org
On June 23, 2021, the NPR station CapRadio reported that Newsom and Cal Fire had falsely claimed in January 2020 that 90,000 acres (36,000 ha) of land at risk for wildfires had been treated with fuel breaks and prescribed burns; the actual treated area was 11,399 acres (4,613 ha), an overstatement of 690%. According to CapRadio, the fuel breaks of the 35 "priority projects" Newsom had touted, which were meant to ensure the quick evacuation of residents while preventing traffic jams and a repeat of events in the 2018 fire that destroyed the town of Paradise, where at least eight evacuees burned to death in their vehicles, were struggling to mitigate fire spread in almost every instance while failing to prevent evacuation traffic jams. The same day CapRadio revealed the oversight, leaked emails showed that Newsom's handpicked Cal Fire chief had ordered the removal of the original statement. In another report in April 2022, CapRadio found a program, hailed in 2020 by the Newsom administration to fast-track environmental reviews on high-priority fire prevention projects, had failed to make progress. KXTV released a series of reports chronicling PG&E's liabilities after committing 91 felonies in the Santa Rosa and Paradise fires. Newsom was accused of accepting campaign donations from PG&E in order to change the CPUC's ruling on PG&E's safety license. The rating change allowed PG&E to avoid billions of dollars in extra fees.
According to the Malaysian Department of Statistics, the country's population was 32,447,385 in 2020, making it the 42nd-most populated country. According to a 2012 estimate, the population is increasing by 1.54% per year. Malaysia has an average population density of 96 people per km2, ranking it 116th in the world for population density. People within the 15–64 age group constitute 70.3% of the total population; the 0–14 age group corresponds to 21.5%; while senior citizens aged 65 years or older make up 8.1%. In 1960, when the first official census was recorded in Malaysia, the population was 8.11 million. 90.1% of the population are Malaysian citizens. Malaysian citizens are divided along local ethnic lines, with 70.6% considered bumiputera. The largest group of bumiputera are Malays, who are defined in the constitution as Muslims who practise Malay customs and culture. They play a dominant role politically. Bumiputera status is also accorded to the non-Malay indigenous groups of Sabah and Sarawak: which includes Dayaks (Iban, Bidayuh, Orang Ulu), Kadazan-Dusun, Melanau, Bajau and others. Non-Malay bumiputeras make up more than half of Sarawak's population and over two-thirds of Sabah's population. There are also indigenous or aboriginal groups in much smaller numbers on the peninsula, where they are collectively known as the Orang Asli. Laws over who receives bumiputera status vary between states. There are also two other non-Bumiputera local ethnic groups. 22.1% of the population are Malaysian Chinese, while 6.5% are Malaysian Indian.
=== Management === Hemoglobin D conditions such as homozygous and HbD/HbA heterozygous do not require medical intervention. HbD/HbS and HbD-thalassemia conditions are managed like the typical cases of sickle cell anemia and thalassemia. In case of sickle cell anemia, daily treatment with penicillin recommended up to five years of age. Dietary supplementation of folic acid is recommended by the WHO. In 2019, Crizanlizumab, a monoclonal antibody was approved by the United States FDA for reducing the frequency of blood vessel blockage in 16 years and older individuals. For thalassemia, regular lifelong blood transfusions is the usual treatment. Bone marrow transplants can be curative for some children. Medications like deferoxamine, deferiprone and luspatercept. Gene therapy, exagamglogene autotemcel is approved for medical use in the United Kingdom since November 2023.
Bilawal Bhutto Zardari (born 21 September 1988) is a Pakistani politician who served as the 37th Minister of Foreign Affairs from 2022 to 2023. He became the chairman of the Pakistan People's Party in 2007 following his mother's assassination. Born in Karachi, Sindh, Bilawal maternally belongs to the Bhutto family and paternally to the Zardari family, he is the son of former Prime Minister Benazir Bhutto and President Asif Ali Zardari, and the grandson of former President Zulfikar Ali Bhutto. Bilawal Zardari was a member of the National Assembly of Pakistan from 2018 to 2023. He was re-elected as a Member of the National Assembly of Pakistan in the 2024 Pakistani general election from newly formed constituency NA-194 Larkana-I, taking oath in 2024.
Sources: en.wikipedia.org
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.
It normally reports the share of the chromatographic signal that belongs to the main peak, not a measure of activity. A high figure means few related substances were detected under the stated method and wavelength. Different laboratories and methods can return different values for the same material.
Retention time alone is weak evidence, because unrelated peptides can elute at similar positions. Amino acid analysis or peptide mapping gives stronger sequence information when a mass spectrometer is unavailable. Most laboratories still treat mass confirmation as the standard step for verifying the correct compound.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.